Free Shipping in the U.S. for orders over $1000. Shop Now>>

What have we been doing?

Read all the latest news from NeoBiotechnologies.

What is causing the surge in cancer among young people? Dr. Tandon advocates for the continued investment on treatment research.

Dr. Atul K. Tandon discusses the differences between targeted cancer therapy and chemotherapy

NeoBiotechnologies Receives 2023 Best of Union City Award

Dr. Atul Tandon, Founder of NeoBiotechnologies, named one of the Top 10 Global Leaders from AIIMS Alumni – 2023

CITATION: Practical implications of androgen receptor inhibitors for prostate cancer treatment

CITATION: Clinical-Grade Validation of an Autofluorescence Virtual Staining System With Human Experts and a Deep Learning System for Prostate Cancer

Dr. Atul K. Tandon of NeoBiotechnologies discusses the NLRP3/caspase1/IL-18 signaling pathway in the treatment of eosinophilic esophagitis (EoE)

Leading biotech company launches exclusive license to 10,000 validated antibodies, elevating cancer research efforts worldwide

NeoBiotechnologies Unveils Critical Portfolio of Mouse & Rabbit Monoclonal Antibodies for Cancer Research & Diagnosis

NeoBiotechnologies interviewed by BioSpace regarding Lean, Fractional C-Suites

Dr. Atul K. Tandon quoted in Pharmaceutical Press’ article on What Techniques Effectively Educate Doctors About New Medications

Dr. Atul K. Tandon talks to GritDaily about overcoming resistance to technological change

NeoBiotechnologies And CDI Laboratories Form Alliance To Distribute CDI’s 2500 Monospecific Transcription Factor Antibodies

Ximbio Partnership Helps Expand NeoBiotechnologies’ Hybridoma Collection

PARTNERSHIP OPPORTUNITIES

NeoBiotechnologies holds Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.

LETS TALK